Vol. 30.Issue. 2. July - December 2025

Treatment for hepatocellular carcinoma after immunotherapy

Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan

Ann Hepatol. 2025;30:101781

Full text access

Share

Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma

Marìa Margarita Anders, Angelo Z. Mattos, José D. Debes, Oscar Beltran, Pablo Coste, Juan Ignacio Marín, Aline Lopes Chagas, Josemaría Menéndez, ... Federico Piñero

Ann Hepatol. 2025;30:101905

Full text access

Share

Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?

Mingyu Sun, Ziyi Yang, Fei Tang, Fenghui Li, Qing Ye, Chao Sun, Jing Liang

Ann Hepatol. 2025;30:101927

Full text access

Share

Chronic hepatitis B virus persistence: Mechanisms, consequences and implications for achieving cure

Christopher Georgi, Simmone D’Souza, Carla Osiowy, Carla S. Coffin, Curtis L. Cooper

Ann Hepatol. 2025;30:101938

Full text access

Share

Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults

Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu

Ann Hepatol. 2025;30:101583

Full text access

Share

A comprehensive meta-analysis of stem cell therapy for liver failure: Assessing treatment efficacy and modality

Shenglong Lin, Haibing Gao, Huaxi Ma, Ziyuan Liao, Dongqing Zhang, Jinshui Pan, Yueyong Zhu

Ann Hepatol. 2025;30:101586

Full text access

Share

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study

Xiumei Jiang, Pan Wang, Ke Su, Han Li, Hao Chi, Fei Wang, Yu Liu, Ke Xu

Ann Hepatol. 2025;30:101578

Full text access

Share

Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease

Shan Hong, Yiwei Hao, Lei Sun, Ping Li, Junru Yang, Fuyang Zhang, Lingling He, Jing Zhang, Hongshan Wei

Ann Hepatol. 2025;30:101589

Full text access

Share

Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018

Siwei Yang, Jianan Yu, Qiyang Chen, Xuedong Sun, Yuefeng Hu, Tianhao Su, Jian Li, Long Jin

Ann Hepatol. 2025;30:101585

Full text access

Share

Trends in the incidence and prevalence of cirrhosis in Manitoba, Canada: A population-based study (2010-2019)

Nabiha Faisal, Lisa M. Lix, Randy Walld, Alexander Singer, Leanne Kosowan, Harminder Singh, Eberhard Renner, Alyson Mahar

Ann Hepatol. 2025;30:101581

Full text access

Share

The effects of HAPA theory-based case management in patients with metabolic dysfunction-associated steatotic liver disease

Jia Mei, Yuncai Xie, Pingping Huang, Yudi Jin, Xia Wang, Ying Chen

Ann Hepatol. 2025;30:101790

Full text access

Share

Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)

Zobair M. Younossi, James M. Paik, Linda Henry, Richard F. Pollock, Maria Stepanova, Fatema Nader

Ann Hepatol. 2025;30:101789

Full text access

Share

The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma

Ming Chen, Yuan Yang, Guangsheng Hu, Zhong Peng, Wu Wen

Ann Hepatol. 2025;30:101776

Full text access

Share

Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis

Jiaxin Zhao, Huiying Zhou, Rui Wu, Chen Ruan, Cheng Wang, Jiawei Ding, Tao Zhang, Zheyu Fang, ... Zhenhua Hu

Ann Hepatol. 2025;30:101579

Full text access

Share

Association between red blood cell indices and non-alcoholic fatty liver disease: Prospective study and two-sample Mendelian randomization analysis based on large cohorts

Rui-ning Li, Qi-mei Li, Sheng-xing Liang, Chang Hong, Rong-feng Zhang, Jia-ren Wang, Hong-bo Zhu, Hao Cui, ... Lu-shan Xiao

Ann Hepatol. 2025;30:101775

Full text access

Share

Study on the prediction model of liver cancer based on chronic liver disease and the related molecular mechanism

Xiaojing Zhang, Xinye Chen

Ann Hepatol. 2025;30:101572

Full text access

Share

Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis

Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong

Ann Hepatol. 2025;30:101780

Full text access

Share

Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045

Chengxia Kan, Kexin Zhang, Yuqun Wang, Xiaofei Zhang, Chang Liu, Yanhui Ma, Ningning Hou, Na Huang, ... Xiaodong Sun

Ann Hepatol. 2025;30:101898

Full text access

Share

Burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990-2021: Results from the Global Burden of Disease study, 2021

Duanyu Wang, Minghao Tan, Socheat Touch, Samnang Kouy, Syphanna Sou, Kun Liu, Youwen Zhu, Hong Zhu, Pengkhun Nov

Ann Hepatol. 2025;30:101906

Full text access

Share

Prevalence of hepatic encephalopathy in non-cirrhotic portal hypertension: A systematic review and meta-analysis

Iris Campos Lucas, Edmundo Pessoa Lopes, Norma Arteiro Filgueira, Caroline Louise Diniz Pereira, Thais Campos Lucas, Ana Lúcia Coutinho Domingues

Ann Hepatol. 2025;30:101902

Full text access

Share

Naringenin attenuates early hepatocarcinogenesis induced by a MASH model

Linda Vanessa Márquez-Quiroga, Aline Barboza-López, Jose Y. Suárez-Castillo, Irina Cardoso-Lezama, Miguel Á. Fuentes-Figueroa, Eduardo E. Vargas-Pozada, Juan D. Rodriguez-Callejas, Erika Ramos-Tovar, ... Pablo Muriel

Ann Hepatol. 2025;30:101897

Full text access

Share

Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis

Shun Li, Lichen Shi, Cheng Huang, Min Li, Tongtong Meng, Hao Wang, Xinyu Zhao, Xiaoqian Xu, ... Yuanyuan Kong

Ann Hepatol. 2025;30:101921

Full text access

Share

Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma

Cyrollah Disoma, Claudio Tiribelli, Caecilia Sukowati

Ann Hepatol. 2025;30:101932

Full text access

Share

Development and evaluation of percentile curves of serum alanine aminotransferase in older adults: A multi-cohort study

Yu Zhang, Shuwen Li, Kang Fu, Kailu Fang, Luyan Zheng, Yushi Lin, Yang Zheng, Jie Wu

Ann Hepatol. 2025;30:101918

Full text access

Share

Development of a prediction index for persistent acute kidney injury following orthotopic liver transplant

Noemi Del Toro-Cisneros, Francisco Javier Antiga-López, Karina C. Felix-Bauer, Adela Uribe-Pérez, Luis Angel Rivas-Sánchez, Nayelli C Flores-García, Ignacio García-Juárez, Olynka Vega-Vega

Ann Hepatol. 2025;30:101923

Full text access

Share

Acute kidney injury incidence and clinical features: Refractory versus non-refractory ascites

Neha Tiwari, Chinmay Bera, Nazia Selzner, Cynthia Tsien, Florence Wong

Ann Hepatol. 2025;30:101922

Full text access

Share

Non-alcoholic fatty liver disease, in contrast to alcoholic liver disease, is associated with lower socio-economic status: results from a German referral center

Semjon Bugaichuk, Verena Wilkens, Karoline Horvatits, Samuel Huber, Ansgar W. Lohse, Johannes Kluwe, Sven Pischke, Thorben Fründt

Ann Hepatol. 2025;30:101926

Full text access

Share

Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression

Kuan-Chang Lai, Te-Lin Hsu, Shih-Yao Lin, Nai-Jung Chiang, Ming‑Huang Chen, Yee Chao, Muh-Hwa Yang, San-Chi Chen

Ann Hepatol. 2025;30:101917

Full text access

Share

Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates

Liang Wang, Shipeng Ma, Lajpat Rai Malhi, Xiaoping Wu, Liping Liu, Xin Wan, Yuliang Zhang, Xiaopeng Li, Shanfei Ge

Ann Hepatol. 2025;30:101925

Full text access

Share

Secular trends and survival impact of high proportion of curative treatments for hepatocellular carcinoma in Taiwan, 2011–2019

Kwong-Ming Kee, Chien-Hung Chen, Tsang-Wu Liu, Yi-Hsiang Huang, Jui-Ting Hu, Gar-Yang Chau, Kuo-Hsin Chen, Chun-Ju Chiang, ... Sheng-Nan Lu

Ann Hepatol. 2025;30:101943

Full text access

Share

Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE

Nikolaj Torp, Louise China, Mads Israelsen, Ewan Forrest, Nick Freemantle, Jonel Trebicka, Aleksander Krag, Alastair O’Brien

Ann Hepatol. 2025;30:101941

Full text access

Share

Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: A United States cohort

Leandro Sierra, Bryan Ferrigno, Ana Marenco-Flores, Marwan Alsaqa, Natalia Rojas, Romelia Barba, Daniela Goyes, Esli Medina-Morales, ... Alan Bonder

Ann Hepatol. 2025;30:101945

Full text access

Share

Demographic and clinical characteristics of MASLD and Met-ALD patients: Insights from NHANES 2017–2020

Jing Liang, Huning Xu, Xueqi Li, Xiaohui Qiao, Hong Ding

Ann Hepatol. 2025;30:101944

Full text access

Share

Changing profile and burden of hepatocellular carcinoma in Arab Countries in 1990–2021

Ziyan Pan, Abdulla Al Hassani, Mona H. Ismail, Khalid M. AlNaamani, Munira Y Altarrah, Moutaz Derbala, Maheeba Abdulla, Hussein El Amin, ... Mohammed Eslam

Ann Hepatol. 2025;30:102104

Full text access

Share

A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined as a comprehensive treatment for hepatocellular carcinoma

Bingzheng Yan, Zhikai Yang, Cong Liu, Haifang Wang, Yuguo Zhang, Dawei Yang

Ann Hepatol. 2025;30:102106

Full text access

Share

Granulomatous liver disease in a referral center in Mexico city

Jesús Ruiz-Manríquez, Sandra M. Feria-Agudelo, Antonio Olivas-Martinez, Froylan D. Martínez-Sánchez, Daniel Azamar-Llamas, Miriam Bobadilla-del-Valle, Orlando Emmanuel Falcón-Antonio, Braulio Martínez-Benítez, ... Edgar Ortiz-Brizuela

Ann Hepatol. 2025;30:102108

Full text access

Share

Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide

Mikkel Parsberg Werge, Adrian McCann, Elias Badal Rashu, Shi Min Lam, Liv Eline Hetland, Mira Thing, Puria Nabilou, Anders Ellekaer Junker, ... Lise Lotte Gluud

Ann Hepatol. 2025;30:102107

Full text access

Share

Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group

Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, ... Mario G. Pessoa

Ann Hepatol. 2025;30:101903

Full text access

Share

“Hepatocellular carcinoma surveillance: Current challenges in Latin America”

Josefina Pages, Manuel Mendizabal, Graciela Castro-Narro, Jose María Menéndez, Oscar Beltran, Leonardo Gomes Da Fonseca, Jaime Poniachik Teller, Marcos Girala, ... special group of interest of liver cancer from the American Association Study for Liver Diseases (ALEH)

Ann Hepatol. 2025;30:101935

Full text access

Share

Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management

Victoria Mainardi, Josefina Pages, Josemaría Menendez, Rodrigo Zapata, Luis Antonio Díaz, Sebastian Marciano, Fernando Cairo, Martin Padilla-Machaca, ... Alejandra Villamil

Ann Hepatol. 2025;30:101939

Full text access

Share

Diastolic dysfunction: Prevalence and outcome in liver transplantation candidates

Francis Voet, Maxim Khalenkow, Michel De Pauw, Xavier Verhelst, Sander Lefere, Anja Geerts, Hans Van Vlierberghe, Sarah Raevens

Ann Hepatol. 2025;30:101784

Full text access

Share

A putative hepatitis B virus sequence motif associated with hepatocellular carcinoma in South African adults

Tongai G. Maponga, Anna L. McNaughton, Cori Campbell, Mariateresa de Cesare, Jolynne Mokaya, Sheila F. Lumley, David Bonsall, Camilla LC Ip, ... Philippa C Matthews

Ann Hepatol. 2025;30:101763

Full text access

Share

A global comparison of hepatitis B & C drug pricing

Leah Yao, Xiaohan Ying, Getan Malik, Catherine Tsai, Arun B. Jesudian, Robert S. Brown Jr., Stephen E. Congly

Ann Hepatol. 2025;30:101928

Full text access

Share

Hepatic arterioportal fistula after biopsy conditioning portal hypertension: first case in primary biliary cholangitis and a systematic literature review

Camilla Gallo, Pietro Invernizzi

Ann Hepatol. 2025;30:101924

Full text access

Share

Identifying patients with undiagnosed primary biliary cholangitis using a clinical management process

Agustin Castiella, Maria José Sánchez-Iturri, Jon Stampa, Beatriz Fernandez, Iñigo Garaizabal, Alvaro Prada, Silvia Torrente, Leire Aburruza, Eva Zapata

Ann Hepatol. 2025;30:101933

Full text access

Share

New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile

Maria Spencer-Sandino, Franco Godoy, Laura Huidobro, Danilo Alvares, Francisco Cruz, Claudia Marco, Macarena Garrido, Daniel Cabrera, ... Catterina Ferreccio

Ann Hepatol. 2025;30:101919

Full text access

Share

Future directions of stem cell therapy for liver failure: Insights from a meta-analysis

Shenglong Lin, Haibing Gao, Yueyong Zhu

Ann Hepatol. 2025;30:101912

Full text access

Share